Capstone Holding Corp.
CAPS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CAPS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CAPS
Capstone Holding Corp. (CAPS) is a biotechnology company focused on developing novel peptides and other molecules for underserved medical conditions, with a current emphasis on its AEM-28 program and joint venture activities.
Key risk: Liquidity and Capital Constraints
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Capstone Holding Corp. (CAPS) is a biotechnology company focused on developing novel peptides and other molecules for underserved medical conditions, with a current emphasis on its AEM-28 program and joint venture activities.
- Cash & equivalents of $0.2M as of 2026-06-30 [sec].
- Total revenue of $21.5M as of 2026-06-30 [sec].
- Net loss of -$1.4M as of 2026-06-30 [sec].
- Shareholders' equity of $12.4M and total debt of $17.1M as of 2026-06-30 [sec].
What works
- The company has a long history of developing novel peptides and other molecules for underserved medical conditions, indicating a focused R&D strategy [sec_mda · as of 2019-05-13].
- Capstone has engaged in joint ventures to advance its AEM-28 program, which may provide collaborative resources and risk-sharing [sec_mda · as of 2019-08-13].
What to weigh
- The company has a very limited cash position of $0.2M as of 2026-06-30, which may constrain operations and development activities [sec].
- Capstone has a history of net losses, with a net loss of -$1.4M as of 2026-06-30, indicating ongoing financial challenges [sec].
- The company faces significant uncertainty in obtaining additional financing, as noted in forward-looking statements regarding the need for capital and potential cost reduction measures [sec · filed 2026-06-29].
- The development of AEM-28 and its analogs requires substantial additional capital, and the company cannot predict the amount needed or the availability of funding [sec_mda · as of 2018-11-06].
From the filings
Quoted directly from source documents.
The company's need for additional financing and potential cost reduction measures.
“our need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all;”
SEC filings · June 29, 2026
The company's focus on developing novel peptides and other molecules.
“Capstone Therapeutics Corp. (the "Company", "we", "our" or "us") is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions.”
SEC MD&A · May 13, 2019
The uncertainty of obtaining additional funding for AEM-28 development.
“We cannot currently predict the amount of funds that will be required if we choose to extend the development activities of AEM-28 and its analogs and to continue operations.”
SEC MD&A · November 6, 2018
Risks & what to watch (4)›
Key risks
- Liquidity and Capital Constraints — Cash of only $0.2M as of 2026-06-30 may not sustain operations without additional financing [sec].
- Dependence on External Financing — The company requires additional capital to continue development of AEM-28 and analogs, with no guarantee of availability [sec_mda · as of 2018-11-06].
- Historical Net Losses — Net loss of -$1.4M as of 2026-06-30 reflects ongoing financial challenges [sec].
- Limited Revenue-Producing Operations — Since selling its Bone Device Business in 2003, the company has relied on cash and investments rather than operational revenue [sec_mda · as of 2019-08-13].
What to watch
- Ability to secure additional equity or debt financing to support operations and development [sec · filed 2026-06-29].
- Progress and funding status of the AEM-28 joint venture and its analogs [sec_mda · as of 2019-08-13].
- Any cost reduction measures or strategic alternatives if financing is not obtained [sec · filed 2026-06-29].
- Updates on the company's cash runway and liquidity position in future filings [sec].
Sources: Competitor trials · News · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Capstone Holding Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Capstone Holding Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
63.2 months
D/E 3.40
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$57K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 61,702 | $41K |
| xtx topco ltd | 23,220 | $15K |
| morgan stanley | 1 | $1 |
| citigroup inc | 1 | $1 |
Short Interest
as of May 20, 2026- % of float
- 6.3%
- Days to cover
- 0.0
- Shares short
- 199,019
- Daily short volume (Jul 1, 2026)
- 60.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CAPS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Capstone Holding Corp.?
Capstone Holding Corp. (CAPS) is a biotechnology company focused on developing novel peptides and other molecules for underserved medical conditions, with a current emphasis on its AEM-28 program and joint venture activities.
Who is the CEO of Capstone Holding Corp.?
Mr. Matthew E. Lipman is the chief executive officer of Capstone Holding Corp. (CAPS).
Where is Capstone Holding Corp. headquartered?
Capstone Holding Corp. (CAPS) is headquartered in Alsip, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.